Tandem autologous hematopoietic stem cell transplantation for patients with multiple myeloma: a systematic review and meta-analysis

ABSTRACT

To evaluate whether patients with multiple myeloma (MM) could benefit from tandem autologous hematopoietic stem cell transplantation (auto-HSCT), PubMed, Embase, Web of Science and Cochrane Library databases were systematically searched, and 10 eligible studies were included after data extraction and quality evaluation. Meta-analysis showed that compared to single autologous hematopoietic stem cell transplantation, tandem auto-HSCT does not improve OS, EFS or efficacy in MM patients, and may even lead to higher treatment-related mortality (TRM). MM patients who received autologous tandem allogeneic HSCT did not achieve better response compared to tandem autologous HSCT. In summary, compared to single autologous hematopoietic stem cell transplantation, tandem autologous hematopoietic stem cell transplantation cannot provide survival advantages for MM patients, and MM patients cannot benefit from autologous tandem allogeneic hematopoietic stem cell transplantation.

KEYWORDS:

• Tandem autologous transplantation
• multiple myeloma
• prognosis
• meta-analysis

Disclosure statement

No potential conflict of interest was reported by the author(s).

Ethics approval and consent to participate

This study was subject to approval by the Research Ethics Committee of Tianjin Medical University Cancer Institute and Hospital and Institute of Hematology and Blood Diseases Hospital.

Consent for publication

Not applicable.

Availability of data and material

The data sets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Additional information

Funding

C.T. is supported by the Natural Science Foundation of Xinjiang Autonomous Region: [Grant Number 2022D01A09].